Literature DB >> 1379882

Risperidone in the treatment of chronic schizophrenic patients: an international double-blind parallel-group study versus haloperidol. The International Risperidone Research Group.

F Müller-Spahn1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1379882     DOI: 10.1097/00002826-199201001-00048

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


× No keyword cloud information.
  7 in total

Review 1.  Mechanisms of action of atypical antipsychotic drugs: a critical analysis.

Authors:  B J Kinon; J A Lieberman
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 2.  Antipsychotic medication for early episode schizophrenia.

Authors:  John Bola; Dennis Kao; Haluk Soydan
Journal:  Cochrane Database Syst Rev       Date:  2011-06-15

3.  Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers.

Authors:  J J Miceli; K D Wilner; R A Hansen; A C Johnson; G Apseloff; N Gerber
Journal:  Br J Clin Pharmacol       Date:  2000       Impact factor: 4.335

4.  Once daily risperidone in treatment of schizophrenia.

Authors:  V Agarwal; R K Chadda
Journal:  Indian J Psychiatry       Date:  2001-01       Impact factor: 1.759

5.  Risperidone in Indian patients with schizophrenia.

Authors:  A K Agarwal; V S Bashyam; S M Channabasavanna; H S Dhavale; M A Khan; S Khanna; P V Pradhan; M Katiyar; R Rajkumar; F R Niazi; R K Jalali; R Gowrishankar; S K Mishra; O P Sood
Journal:  Indian J Psychiatry       Date:  1998-07       Impact factor: 1.759

6.  Managing antipsychotic-induced acute and tardive dystonia.

Authors:  M Raja
Journal:  Drug Saf       Date:  1998-07       Impact factor: 5.606

Review 7.  Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia.

Authors:  S Grant; A Fitton
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.